During the pandemic of novel coronavirus infection (COVID-19), computed tomography (CT) showed its effectiveness in diagnosis of coronavirus infection. However, ionizing radiation during CT studies causes concern for patients who require dynamic observation, as well as for examination of children and young people. For this retrospective study, we included 15 suspected for COVID-19 patients who were hospitalized in April 2020, Russia. There were 4 adults with positive polymerase chain reaction (PCR) test for COVID-19. All patients underwent magnetic resonance imaging (MRI) examinations using MR-LUND PROTOCOL: Single-shot Fast Spin Echo (SSFSE), LAVA 3D and IDEAL 3D, Echo-planar imaging (EPI) diffusion-weighted imaging (DWI) and Fast Spin Echo (FSE) T2 weighted imaging (T2WI). On T2WI changes were identified in 9 (60,0%) patients, on DWI – in 5 (33,3%) patients. In 5 (33,3%) patients lesions of the parenchyma were visualized on T2WI and DWI simultaneously. At the same time, 4 (26.7%) patients had changes in lung tissue only on T2WI. (P(McNemar) = 0,125; OR = 0,00 (95%); kappa = 0,500). In those patients who had CT scan, the changes were comparable to MRI. The results showed that in case of CT is not available, it is advisable to conduct a chest MRI for patients with suspected or confirmed COVID-19. Considering that T2WI is a fluid-sensitive sequence, if imaging for the lung infiltration is required, we can recommend the abbreviated MRI protocol consisting of T2 and T1 WI. These data may be applicable for interpreting other studies, such as thoracic spine MRI, detecting signs of viral pneumonia of asymptomatic patients. MRI can detect features of viral pneumonia.
Artificial intelligence technologies in medical practice are a promising direction in the world. Artificial intelligence medical decision support systems, diagnostic and screening programs can help medical personnel in routine and complex tasks and improve the level of medical care provided to patients. At the same time, the development, production and distribution of artificial intelligence systems must be regulated without fail. Registration and subsequent control (post-registration monitoring) of artificial intelligence systems in medicine require the creation, adjustment of the legal framework and technological regulation. The Russian Federation has developed a promising development strategy in this area. Seven national standards have been developed by experts in the field of Artificial intelligence in healthcare. These standards establish the procedures for conducting clinical and technical trials, performance requirements and the concept of life cycle, a quality management system and risk management. Aseparate standards is devoted to dataset creation for training and testing the developed algorithms, requirements for them and a metadata format. There are plans to bring the developed national standards to the international level, which will allow Russian manufacturers of artificial intelligence systems implemented these national standards to comply with foreign counterparts and become more competitive at the international level. The international community has already supported the development of an ISO standard based on the national standard for clinical trials. The development will be performed based on the technical committee ISO/TC215 (Health informatics) in conjunction with ISO/IEC JTC1/SC42 (Artificial intelligence), this will allow bringing the national requirements for the Artificial intelligence to the international level. The cycle of these standards will summarize recognized methodologies, helping both manufacturers and medical organizations, doctors and patients to produce and use aquality, safe and effective product.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.